Original Research

Inhibition of PFKFB3 Expression Stimulates Macrophage-Mediated Lymphangiogenesis Post-Acute Myocardial Infarction

Tianyi Cui¹, Chao Feng²,³,*, Hantao Jiang², Ying Jin², Jinping Feng²,³,*

¹State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 301617 Tianjin, China
²Department of Cardiology, Tianjin Chest Hospital, 300222 Tianjin, China
³Tianjin Key Laboratory of Cardiovascular Emergency and Critical Care, Tianjin Municipal Science and Technology Bureau, Tianjin Chest Hospital, 300222 Tianjin, China

*Correspondence: fengchao@nankai.edu.cn (Chao Feng); fjptj666@163.com (Jinpeng Feng)

1. Introduction

Acute myocardial infarction (AMI) represents a substantial danger to human health, attributable to its heightened prevalence and mortality rates [1,2]. Although medication, interventional therapy, and cardiac surgery are commonly employed to treat AMI, incomplete reperfusion, and the existence of extensive or multiple infarcted areas may result in left ventricular (LV) remodeling [1,3]. This process may further aggravate the advancement of heart failure (HF), which is clinically identified as ischemia-reperfusion (I/R) injury [1,3]. The current focus for cardiovascular disease pertains to the suppression of the advancement of ventricular remodeling caused by I/R, and the identification of efficacious therapeutic approaches and targets.

The emergence of therapeutic lymphangiogenesis as a potential solution to reduce inflammation and ventricular remodeling after an acute myocardial infarction has shown promise in preventing the onset of heart failure [4–6]. Recent research has substantiated the advantageous impact of lymphatic vessels in the course of cardiac remodeling [4,5]. Following AMI, the upregulation of vascular endothelial cell growth factor C (VEGF-C) stimulates the expression of lymphatic growth factor, which promotes the development of cardiac lymphatic vessels, and ultimately, improves cardiac function [7]. Additionally, the cardiac lymphatic system is associated with the subsiding of inflammation following myocardial infarction [5]. Notably, CD11b⁺ macrophages have been observed to secrete VEGF-C, thereby promoting lymphangiogenesis [8,9].

The metabolic reprogramming of macrophages, specifically their adoption of aerobic glycolysis or the Warburg effect, has emerged as a significant mechanism driving the conversion of macrophages into inflammatory phenotypes [10,11]. The PFKFB enzymes are a subset of glycolytic regulators that facilitate the production of fructose-2,6-bisphosphate (F-2,6-P2) [12]. The PFKFB3 isoform is the dominant isoform among the four PFKFB isoforms, and it is primarily expressed in vascular cells, leukocytes, and many transformed cells. Nevertheless, the connection between the aerobic glycolysis of macrophages and lymphangiogenesis, and the regulatory function of PFKFB3 in this regard, is yet to be fully understood.
The present study elucidates the correlation between macrophage aerobic glycolysis and the expression of VEGF-C induced by macrophages. It has been preliminarily established that hampering the expression of PFKFB3 in macrophages can augment the production of VEGF-C in macrophages, thereby facilitating lymphatic neogenesis and the amelioration of inflammatory response after I/R.

2. Methods

2.1 Animal Use and Study Approval

All animal and surgical procedures conformed to Directive 2010/63/EU, issued by the European Parliament. All animals were handled according to the guidelines of the TCM Animal Research Committee (TCM-LAEC20221178) of Tianjin University of Traditional Chinese Medicine. C57BL6/J mice (20 ± 20 g) were provided by Beijing Vital River Laboratory Animal Technology (Beijing, China). Lyz2Cre and VEGF-Cfl/fl mice were provided by GemPharmatech (Jiangsu, China). PFKFB3fl/fl mice were provided by Shanghai Biomodel Organism Science & Technology Development (Shanghai, China). Myb6-mCherry B6 D2-ig mice were obtained from The Jackson Laboratory. Male mice were solely utilized as the animal participants in this study. The animals were housed in a specific-pathogen-free (SPF) animal facility in the experimental animal center of Tianjin University of Traditional Chinese Medicine, under controlled temperature (22 ± 2 °C) and humidity (40 ± 5%), and with a 12 hours light/dark cycle, and received a standard pellet diet with continual access to water.

2.2 Transfected and Transgenic Animal Procedures

Specific VEGFR3 knockdown or overexpression was achieved in the left ventricles of the mice by using adeno-associated viruses-based (AAV9) delivery vectors (Genechem, Shanghai, China). AAV9 expressing the VEGFR3 open reading frame (titer: 1.76 × 10^{12}), CCR2-shRNA (titer: 1.65 × 10^{12}), or a scrambled control sequence bearing no homology to known gene transcripts (titer: 1.54 × 10^{12}) were injected into the left ventricle at multiple sites. After a period of 30 days, the mice were subjected to I/R surgery and subsequent treatments.

2.3 Ischemia-Reperfusion (I/R) Models

I/R models were prepared according to our previous studies [13,14], and the left anterior descending coronary artery (LAD) was ligated through the utilization of a 6-0 silk suture. Following a duration of 60 minutes, the suture was removed to facilitate reperfusion. The experimental cohort underwent a procedure involving ligation, whereas the control group underwent a sham procedure that mimicked the experimental intervention, although without the actual ligation. In order to apply the VEGFR3 inhibitor as a treatment, mice were subjected to an intraperitoneal injection of MAZ51 at a dose of 10 mg/kg per bodyweight (#676492-10MG, sigma-Aldrich, Shanghai, China), as previously described [15,16].

2.4 Cardiac Functional Measurements

Mice echocardiography was performed using a ultra-high-resolution animal ultrasound imaging system (Vevo 2100, VisualSonics, Toronto, IL, Canada) and the left ventricular function was evaluated as previously described [16]. Long axes were observed through the utilization of M-mode imaging. Three representative cycles were captured for each animal, and measurements were performed for ejection fraction (EF%) and fractional shortening (FS%).

2.5 Cell Culture

Bone marrow-derived macrophages (BMDM) were procured from bone marrow, utilizing the previously established method [17,18]. The femur bones of the mice were subjected to sterilization via a 10-minute treatment with 75% ethanol, followed by flushing using Iscove’s Modified Dulbecco’s Medium (IMDM), containing 2% fetal bovine serum (FBS). After treating the red blood cells with red blood cell lysis buffer, the entire solution was centrifuged. Then, the resulting cell pellet was suspended in fresh IMDM containing 10% FBS and 20 ng/mL GM-CSF. Cells were all cultured in a humidified incubator at 37 °C and 5% CO₂. Cell cultures were replenished with fresh IMDM every third day. After a period of 10 days, the macrophages were acquired. The polarization of macrophages towards M1 can be achieved by subjecting them to 1 µg/mL LPS (Sigma-Aldrich, #L4391-10X1MG) and 50 ng/mL IFN-γ (#APA033Mu61, Cloud-Clone Corp, Wuhan, China) stimulation for a duration of 24 hours. The inhibition of macrophage glycolysis was achieved through the implementation of 3PO (10 µM/L; #HY-19824, MedChemExpress, Shanghai, China). For cell transfections, macrophages were stably transfected with VEGFR-overexpressing lentivirus (Genechem, Shanghai, China) or lentivirus containing scrambled control sequences. Briefly, macrophages were inoculated into 6-well plates and cultured at 37 °C. The infection reagent and lentivirus were added to macrophages for 72 hours, according to the manufacturer’s instructions. All cell lines were validated by STR profiling and tested negative for mycoplasma.

2.6 Fluorescence-Activated Cell Sorting (FACS) and Flow Cytometry Analysis

For single-cell suspensions, the Multi-Tissue Dissociation Kit 2 (#130-110-203, Miltenyi, Bergisch Gladbach, Germany) and gentleMACS Dissociator device (Miltenyi) were used to dissociate cells from mice hearts. The collected cells were incubated with antibodies at 37 °C for 20 minutes. F4/80⁺ macrophages were isolated and purified using a FACSaria II (BD, Franklin Lakes, NJ, USA) flow cytometer. Flow cytometry was performed using a
Flow Cytometer (NovoCyte, Agilent, Santa Clara, CA, USA). Data were analyzed using FlowJo software (Version V10.8; TreeStar, Ashland, OR, USA) and NovoExpress (Version 15.0; Agilent). The antibodies used in this study were anti-mouse CD16/32 (TruStain FeX™, Biolegend, San Diego, CA, USA), CD45 antibody, anti-mouse, APC (#130-123-784, Miltenyi); CD11b antibody, anti-human/mouse, FITC (#130-113-796, Miltenyi); PerCP anti-mouse F4/80 antibody (#123126, Biolegend); Ly6G antibody, PE, ebioscience™, REAfinity™ (#12-9668-82, Thermo Fisher, Waltham, MA, USA); APC/cyanine7 anti-mouse Ly-6C antibody (#128026, Biolegend); FITC anti-mouse CD64 antibody (#161008, Biolegend).

2.7 Mitochondrial Respiration and Glycolysis

Extracellular acidification rates (ECARs) were assessed using a Seahorse analyzer (XF96, Agilent), as previously described [19]. Briefly, macrophages were cultured in 96-well plates followed by the sequential addition of 20 mM glucose, 2 µM oligomycin, and 80 mM 2-DG. ECARs in 96-well plates followed by the sequential addition of 20 mM glucose, 2 µM oligomycin, and 80 mM 2-DG. ECARs were calculated using the preloaded Seahorse analyzer software.

2.8 Enzyme-Linked Immunosorbent Assay (ELISA)

Following the collection process, plasma was subjected to centrifugation at a speed of 3000 rotations per minute (rpm) for a duration of 15 minutes to facilitate the estimation of biochemical parameters. ANP and BNP were detected in the plasma using an enzyme-linked immunosorbent assay (ELISA) kit (ANP: #SEA225Mu; BNP: #SEA541Mu, Cloud-Clone Corp), as per the instructions provided by Cloud-Clone Corp.

2.9 Histological Analysis

After being immersed in 4% paraformaldehyde for a duration of 72 hours, the heart tissues were fixed. Subsequently, the tissues were embedded in paraffin and sectioned into 4 µm thick pieces. Then, these sections were subjected to Masson staining. For immunofluorescence (IF) analysis, sections were incubated with LYVE1 (#ab218535, Abcam, Cambridge, MA, USA), Prox1 (#ab199359, Abcam), and CD68 (#ab283654, Abcam) at 4 °C for 12 hours, and subsequently incubated with anti-Rabbit HRP (Alexa Fluor 647) and anti-Mouse HRP (Alexa Fluor 488) at 37 °C for 2 hours. After washing with PBS, the sections were counterstained with DAPI. The sections were examined using a fluorescence microscope and a digital camera (3DHistech, Budapest, Hungary).

2.10 Quantitative Real-Time Polymerase Chain Reaction (RT-PCR)

According to the guidelines provided by the manufacturer (Roche, Basle, Switzerland), mRNA reverse transcription was conducted using the mRNA reverse transcription kit to generate cDNA. RT-PCR was conducted by a CFX96™ PCR detection system (BioRad, Redmond, WA, USA) using the SYBR Green PCR master mix (Roche). GAPDH and U87 were employed as internal reference genes for normalization purposes. All used primer sequences are provided below. GAPDH forward: TGTGTCGGCTGTGAGATCTGA; reverse: CCTGTCCTCACACCTTCTTG. IL-1β forward: TGTTGCTCTGGAGTAGAGGT; reverse: GCCGTGGTTGAGAGATAAG. IL-6 forward: TAGTCCCTCCTACCACTTTGC; reverse: TGGTGTGCTACGCGTGGGCT. PKM2 forward: GTGGAGAGATGCAGAGAGAT; reverse: CAACAGGACGTTGAAGAATGGCAGAGAG. GLUT1 forward: CTGCTTCAACCATCACATCTG; reverse: GCTGTCTCAACTACCCCAATTTCC.

2.11 Statistical Analysis

The data were analyzed using SAS statistical software (v9.4, SAS Institute, Cary, NC, USA). The mean ± standard deviation (SD) was used to present all quantitative data in this study. Pairwise comparisons were conducted using two-tailed Student’s t-tests. To compare differences across multiple groups with a single variable, a one-way analysis of variance (ANOVA) was performed. A p value < 0.05 was considered statistically significant. The figure legends contain all numerical data pertaining to the experiments conducted.

3. Results

3.1. Promoting Lymphatic Regeneration is Beneficial for Heart Repair after I/R

In this research, we utilized intramyocardial injections of adenov-associated viruses (AAV9) to inhibit (VEGFR3 shRNA) or promote the expression of VEGFR3 (VEGFR3 ORF) in the heart. Moreover, to serve as the control groups, AAV9-empty vectors were injected into the myocardium of the sham, I/R, and MAZ51 (a VEGFR3 tyrosine kinase inhibitor that selectively hinders the activation of VEGFR3 caused by VEGF-C) groups. To establish a model of is-
chemic heart failure (HF), the approach of subjecting the heart to 1 hour of cardiac ischemia followed by 14 days of reperfusion (I/R) was employed (Fig. 1A). Cardiac ultrasound was performed to assess the cardiac function of each experimental cohort (Fig. 1B–D). The M-mode pattern of the cardiac ultrasound, which served as a representative, indicated that the state of the left ventricular wall motion was considerably diminished in both the MAZ51 intervention and the VEGFR3 shRNA groups, in contrast to the I/R group. Conversely, the VEGFR3 ORF group significantly improved the state of the left ventricular wall motion following I/R (Fig. 1B). The measurement outcomes of the left ventricular ejection fraction (Fig. 1C, EF%) and short axis shortening rate (Fig. 1D, FS%) demonstrated a consistent trend; notwithstanding the reduction in MAZ51 and VEGFR3 shRNA, where no significant difference was observed, while VEGFR3 ORF displayed a noteworthy augmentation. In contrast to the I/R group, the degree of cardiac fibrosis in mice subjected to I/R and treated with MAZ51 and VEGFR3 shRNA exhibited a significant increase. Conversely, VEGFR3 ORF was found to notably ameliorate cardiac fibrosis in mice (Fig. 1E,F). Therefore, to evaluate lymphatic neogenesis in the heart of I/R mice in diverse experimental groups, immunofluorescence staining of lymphatic markers, such as lymphatic endothelial hyaluronic acid receptor 1 (Lyve1) and homeobox transcription factor 1 (Prox1), was employed. The results demonstrated that the interference of MAZ51 and VEGFR3 shRNA had an adverse impact on the development of cardiac lymphatic vessels in mice that underwent I/R, whereas the administration of VEGFR3 ORF demonstrated a marked improvement and facilitation of cardiac lymphatic neogenesis (Fig. 1G–I). The process of phagocytosis, in which macrophages engulf deceased cells, results in the transportation of cardiac antigens to the mediastinal lymph nodes (MLNs) [20]. In these nodes, the antigens may be presented to T cells, which are already present in the area, by a process known as cross-presentation [21]. Thus, to assess the impact of lymphangiogenesis on the drainage of myocardial cell debris towards the MLNs, an analysis was conducted on the level of cardiogenic (Myh6-mCherry) antigen present in the MLNs. The flow cytometry findings revealed that the number of cardiogenic cherry antigen in the drained MLNs was significantly reduced upon inhibition of lymphangiogenesis (MAZ51 and VEGFR3 shRNA), whereas promoting lymphangiogenesis significantly increased the aforementioned number (Fig. 1J,K). The mRNA expression of genes linked with lymphatic neogenesis, including VEGFR3, VEGF-D, podoplanin (Pdpm), and Ccl21, displayed coherence with the preceding results (Fig. 1L). Furthermore, the serum levels of ANP and BNP (Fig. 1M) are markers of heart failure, indicated that hindering lymphangiogenesis through the use of MAZ51 and VEGFR3 shRNA could considerably accelerate the advancement of the disease. Conversely, promoting lymphangiogenesis yielded contrasting outcomes. In conclusion, the promotion of lymphangiogenesis proved to be advantageous in the restoration of the heart following I/R.

3.2 PFKFB3 Regulates the Production of VEGF-C by Macrophages

The ability to produce VEGF-C has been observed in cells that exhibit macrophage-like characteristics [7]. The current study employed Lys2Cre+ VEGF-Cfl/fl [8] mice to abolish the expression of VEGF-C in macrophages, where Lys2 expression is evident in myeloid cell lines, such as monocytes and fully developed macrophages. The outcomes of immunofluorescence staining for CD68 and Lyve1 revealed that the ablation of VEGF-C expression in macrophages led to a significant decrease in the number of lymphatic vessels following I/R (Fig. 2A,B). The results obtained by flow cytometry analysis revealed that the ablation of VEGF-C expression in macrophages led to a marked increase in the number of macrophages present in the heart (Fig. 2C,D). Furthermore, it caused a significant elevation in the mRNA expression of inflammatory factors, such as IL-1β, IL-6, and TNF-α, in the heart (Fig. 2E). It has been established that the suppression of glycolysis could effectively impede the inflammatory reaction of macrophages [22,23]. However, the correlation between glycolysis inhibition and the production of VEGF-C by macrophages remains ambiguous. Notably, following I/R, there was an up-regulation in the expression of glycolytic-associated genes, including PKM2, GLUT1, PFKFB3, and HK2, within the cardiac macrophages, obtained by flow cytometry (FACS) (Fig. 2F). The glycolytic pressure test revealed a marked elevation in extracellular acidification rates (ECARs) post-I/R, indicating heightened glycolytic activity in cardiac macrophages following this event (Fig. 2G). In order to assess the impact of glycolysis inhibition on lymphatic neogenesis, we employed LPS to provoke inflammation and heighten glycolysis in bone marrow-derived macrophages (BMDM) of I/R mice [24]. Then, we utilized the PFKFB3 inhibitor 3PO to intervene, as well as using adenovirus overexpression of PFKFB3. The outcomes demonstrated that the inhibition of PFKFB3 had a significant impact on the glycolytic activity of BMDM, causing a decrease in its level (Fig. 2H). Moreover, the inhibition of PFKFB3 led to a significant increase in the expression of VEGF-C and VEGF-D in BMDM (Fig. 2I). In addition, 3PO could reduce the glycolysis level of inactive macrophages (Fig. 2H) yet have no considerable influence on the expression of VEGF-C and VEGF-D (Fig. 2I). These results suggested that inhibiting the level of glycolysis in an activated state of macrophages can lead to an increase in the expression of VEGF-C and VEGF-D. Conversely, the overexpression of PFKFB3 resulted in a significant increase in the glycolytic activity of BMDM (Fig. 2I), which was accompanied by a notable decrease in the expression of VEGF-C and VEGF-D (Fig. 2K). To summarize, the expression of PFKFB3 in
Fig. 1. Promoting lymphatic regeneration is beneficial for heart repair after ischemia-reperfusion (I/R). (A) Schematic overview of experimental procedure. (B) Representative image of M-mode in a cardiac ultrasound. Quantification of (C) EF% and (D) FS%, 14 days after I/R, data are presented as mean ± SD of n = 8–10 mice. (E–F) Representative Masson staining of heart transverse sections (scale bar = 1000 µm) and quantified IS/IV (infarct size: IS; left ventricular rate: LV, data are presented as mean ± SD of n = 3. (G–I) Representative immunostaining of Lyve1 and Prox1 in heart transverse sections (scale bar = 20 µm) and quantified Lyve1 and Prox1 area%, data are presented as mean ± SD of n = 3. (J–K) MLNs were harvested, and flow cytometric analysis of CD45+ CD11b+ CD64+ mCherry+ cells was performed, data are presented as mean ± SD of n = 3 mice. (L) The mRNA levels of VEGF-C, VEGF-D, podoplanin (Pdpn), and Ccl21 in heart, data are presented as mean ± SD of n = 3 mice. (M) The levels of ANP and BNP in serum, data are presented as mean ± SD of n = 6 mice. Statistical significance is shown as: **p < 0.01, compared to the Sham group; #p < 0.05 and ##p < 0.01, compared to the I/R group.

Macrophages possesses a strong correlation with the production of VEGF-C. Moreover, it has been observed that hindering the function of PFKFB3 could stimulate the generation of VEGF-C.

3.3 Elimination of Macrophage PFKFB3 could Enhance Lymphangiogenesis Following I/R

In our study, we employed Lys2Cre PFKFB3fl/fl mice to ablate the expression of PFKFB3 in macrophages with the aim of investigating the impact of PFKFB3 on
lymphatic neogenesis in the context of I/R. The findings of the cardiac ultrasound indicate that the inhibition of PFKFB3 expression in macrophages could enhance the left ventricular wall motion in mice following I/R (Fig. 3A), leading to a notable improvement in ejection function (EF%) in mice with I/R (Fig. 3B). According to Mason’s research, the inhibition of PFKFB33 expression in macrophages could decrease the degree of cardiac fibrosis in I/R mice (Fig. 3C,D). Additionally, immunofluorescence staining of Lyve1 and Prox1 confirmed that this intervention resulted in an improvement in lymphatic neogenesis (Fig. 3E–G). The mRNA expressions of VEGF-C, VEGF-D, Pdpn, and Ccl21 were significantly increased following the deletion of PFKFB3 in mice subjected to I/R (Fig. 3H). Flow cytometry was employed to separate cardiac macrophages and qPCR was used to detect the mRNA expression of VEGF-C, IL-1β, IL-6, and TNFα in cardiac macrophages. The results indicated that the expression of VEGF-C in PFKFB3−/− cardiac macrophages was significantly higher than the PFKFB3fl/fl cardiac macrophages (Fig. 3I), and the mRNA expression of IL-1β, IL-6, and TNFα in PFKFB3−/− cardiac macrophages was significantly lower than the PFKFB3fl/fl cardiac macrophages (Fig. 3J). The evidence gathered suggests that PFKFB3 may have a role in modulating the lymphangiogenesis function during I/R injury.

### 3.4 Absence of PFKFB3 in Macrophages Results in Improved Stability of Cardiac Immune Cells Post I/R

The quantification of neutrophils, monocytes, and macrophages in the heart following I/R was assessed through the utilization of flow cytometry (Fig. 4A–D). The findings indicated that the elimination of PFKFB3 resulted in a substantial decrease in the population of neutrophils (Fig. 4B,E), monocytes (Fig. 4C,F), and macrophages (Fig. 4D,G) within the heart of mice undergoing I/R. Ad-
Fig. 3. Elimination of PFKFB3-enhanced lymphangiogenesis following I/R. (A) Representative image of M-mode in a cardiac ultrasound of Lyz2Cre PFKFB3^{+/+} mice. Quantification of (B) EF% after I/R, data are presented as mean ± SD of n = 6 mice. (C,D) Representative Masson staining of heart transverse sections (scale bar = 1000 µm) and quantified IS/IV (infarct size: IS; left ventricular rate: LV, data are presented as mean ± SD of n = 3. (E–G) Representative immunostaining of Lyve1 and Prox1 in heart transverse sections (scale bar = 20 µm) and quantified LYVE1 and Prox1 area%, data are presented as mean ± SD of n = 3. (H) The mRNA levels of heart VEGF-C, VEGF-D, podoplanin (Pdpn), and Ccl21, data are presented as mean ± SD of n = 3 mice. (I) The mRNA levels of VEGF-C in cardiac macrophages, data are presented as mean ± SD of n = 3 mice. (J) The mRNA levels of IL-1β, IL-6, and TNFα in cardiac macrophages, data are presented as mean ± SD of n = 3 mice. Statistical significance is shown as: *p < 0.05 and **p < 0.01, compared to the Sham group.
Fig. 4. Absence of PFKFB3 in macrophages results in improved stability of cardiac immune cells post I/R. (A) Flow cytometric analysis of (B,E) neutrophils (CD11b<sup>+</sup> Ly6G<sup>+</sup>), (C,F) monocytes (CD11b<sup>+</sup> Ly6Chigh/low), and (D,G) macrophages in the heart (CD11b<sup>+</sup> F4/80<sup>+</sup>), data are presented as mean ± SD of n = 3 mice. (H) The heart mRNA levels of IL-1β, IL-6, and TNFα, data are presented as mean ± SD of n = 3 mice. Statistical significance is shown as: **p < 0.01, compared to the Sham group.

Additionally, there was a significant reduction in the expression of inflammatory factors (IL-1β, IL-6, and TNFα) in the heart of Lyz2<sup>Cre</sup> PFKFB3<sup>+/−</sup> mice (Fig. 4H). In brief, our study has substantiated that the elimination of PFKFB3 ex-
pression in macrophages could considerably augment I/R lymphangiogenesis, bolster the robustness of cardiac immune cells, and curtail the inflammatory reaction in the cardiac tissue.

4. Discussion

It has been stated that the amplification of cardiac lymphangiogenesis post-myocardial infarction can enhance cardiac function [4,5]. The current investigation aims to establish a relationship between the aerobic glycolysis of macrophages and the expression of VEGF-C, which is stimulated by macrophages. Based on the initial findings, inhibiting the expression of PFKFB3 in macrophages may enhance the generation of VEGF-C in macrophages, leading to the promotion of lymphatic neogenesis and the mitigation of the inflammatory response following I/R.

It has been previously established that the signal transduction of VEGF-C/PFKFB3 plays a significant role in the regulation of lymphatic neogenesis [25]. The findings of our investigation indicate that impeding or suppressing the VEGF-C/PFKFB3 signals leads to an upsurge in the progression of ventricular remodeling in response to I/R, while augmenting the expression of VEGFR3 plays a salutary role in ameliorating ventricular remodeling after I/R. This process, which is advantageous for repairing the heart, is linked to the growth of lymphatic vessels. Upon the overexpression of VEGFR3, a noticeable increase in the quantity of cardiac antigens was observed in the MLNs. This observation suggests that the overexpression of VEGFR3 facilitates the process of cardiac lymphangiogenesis, which in turn promotes the efficient flow of myocardial cell debris to the MLNs. The aforementioned procedure yields a reduction in the buildup of cellular waste in the cardiac muscle of individuals undergoing I/R, ultimately leading to a mitigation of inflammatory responses. Moreover, the VEGF-C/VEGFR3 signaling pathway plays a crucial role in the modulation of macrophage plasticity [26]. Upon conducting our experiment, we noted an important induction in the mRNA expression of inflammatory factors in the cardiac region following the elimination of VEGF-C expression in Lyz2+ cells. The rise in these inflammatory factors is generally thought to be connected to the activation of macrophages that belong to the M1 type. An upsurge in the number of macrophages was observed in the heart of I/R mice following the targeted removal of VEGF-C expression in Lyz2+ cells. Regrettably, we did not conduct further analysis to determine the influence of VEGF-C in the transformation of cardiac macrophages from the M1 to M2 phenotype. As such, further investigations are imperative to gain a comprehensive understanding of the impact of VEGF-C on the orchestrated reorganization and operation of macrophages.

The general consensus is that M2-type macrophages, recognized for their anti-inflammatory attributes, are implicated in the restorative process of cardiac tissue following an injury [27]. The replacement of M1-type macrophages with M2-type macrophages occurs within 7 to 14 days following an ischemia-reperfusion injury [28,29]. This transformation of a macrophage phenotype is closely associated with changes in their metabolic patterns. To be more precise, M1-type macrophages exhibit a greater reliance on the energy supply mechanism of glycolysis [23]. A hindrance to the glycolytic flow of macrophages is a contributing factor in the conversion of macrophages into the M2 type [23]. LPS has the ability to elicit a shift towards the M1 phenotype by macrophages [24], which is concomitant with a rise in glycolytic flux. During our experiment, we administered a glycolytic inhibitor, 3PO, to LPS-induced BMDM. The evidence gathered from our study indicates that the suppression of the glycolytic flux led to an increase in the expression of VEGF-C and VEGF-D in LPS-stimulated BMDM. This effect may be attributed to the facilitation of the DMBM transformation into a reparative phenotype.

The phagocytic activity of macrophages acts as a trigger for the upregulation of VEGF-C expression by macrophages in the context of tissue damage [30]. The findings of previous research have substantiated that PFKFB2-mediated glycolysis is capable of promoting sustained phagocytosis, which is driven by lactic acid in macrophages [24]. In contrast, the inhibition of phagocytosis is observed when macrophages silence PFKFB2. Although our experimental findings contradict this outcome, it is significant to note that the manner in which macrophage PFKFB2 phosphorylation promotes an increase in phagocytosis is separate from the approach through which macrophage inflammation triggers glycolysis, as highlighted in this particular study [24]. In view of the adaptable and intricate nature of macrophages, particularly their diverse functions in the context of heart damage and recovery (whether it involves repair, injury, or both), it remains imperative to differentiate more precisely between the various subtypes of macrophages and their respective regulatory impacts on the formation of lymphangiogenesis following heart injury.

It is important to note that our experimental conclusions have limitations. The action of Lyz2Cre+ could also result in the removal of PFKFB3 from both monocytes and granulocytes. Our study solely concentrated on the impact of the macrophage PFKFB3 on lymphangiogenesis after 14 days of I/R, without taking into consideration its influence on lymphangiogenesis during the initial and intermediate stages following I/R. One must acknowledge the contrasting phenotypes and functions of macrophages during the early and middle stages of post-I/R compared to those at the 14-day mark. Furthermore, it is imperative to recognize the contribution of VEGF-C from alternative sources, such as vascular endothelial cells.

5. Conclusions

Our initial investigations suggest that the suppression of PFKFB3 expression in macrophages could potentially
stimulate the production of VEGF-C in these immune cells, which may facilitate lymphangiogenesis and mitigate the inflammatory effects of I/R injury.

Availability of Data and Materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author Contributions
TC: Conceptualization, Methodology, Investigation, Writing — Original Draft, Visualization, Resources and Formal analysis; CF: Conceptualization, Methodology, Investigation, Writing — Original Draft, Visualization, Resources and Formal analysis; HJ: Conceptualization, Methodology, Investigation, Writing — Original Draft, Visualization, Resources and Formal analysis; YJ: Conceptualization, Methodology, Investigation, Writing — Original Draft, Visualization, Resources and Formal analysis; JF: Conceptualization, Methodology, Investigation, Writing — Original Draft, Visualization, Resources and Formal analysis; Project administration and Funding acquisition. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Ethics Approval and Consent to Participate
All animal and surgical procedures conformed to Directive 2010/63/EU issued by the European Parliament. All animals were handled according to the guidelines of the TCM Animal Research Committee (TCM-LAEC2021409) of Tianjin University of Traditional Chinese Medicine.

Acknowledgment
Not applicable.

Funding
This research was funded by Tianjin Key Medical Discipline (Specialty) Construction Project; Tianjin Science and Technology Plan Project (21JCZDJC00600, JF); Tianjin Health Science and Technology Project (ZC20011, JF).

Conflict of Interest
The authors declare no conflict of interest.

References


